Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Race Oncology Ltd has announced a change in the director’s interest, with Dr. Peter Smith acquiring 9,433 fully paid ordinary shares through an on-market purchase. This transaction reflects a strategic move by the director, potentially indicating confidence in the company’s future performance and aligning his interests with those of the shareholders.
More about Race Oncology Ltd.
Race Oncology Ltd is a company operating in the biotechnology industry, focusing on the development and commercialization of cancer therapeutics. The company is primarily engaged in advancing its lead drug candidate, Bisantrene, which targets various forms of cancer, aiming to improve patient outcomes through innovative treatment solutions.
Average Trading Volume: 561,846
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$518.1M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.